Abstract 28P
Background
The purpose of the study was to evaluate the toxicity, local control, overall and disease-free survival of elderly breast cancer (BC) patients treated with adjuvant once-weekly ultra-hypo fractionated radiotherapy (RT) either with intensity-modulated RT (IMRT) or 3D conformal RT (3DCRT).
Methods
From 2019 to 2022, patients with BC receiving RT in dose 5.2 Gy in one week to the partial breast after breast-conserving surgery were considered for the study. Inclusion criteria were: T1–T2 invasive BC, no axillary involvement, age ≥ 60 years.
Results
A total of 154 patients were included in the study. Median age was 71 (61–86) years. Most of BC were T1 (24.7%), while the remaining were T2 (75.3%). The only severe acute toxicity (G3) at the end of RT was erythema (1.3%), registered in the 3DCRT group. With 24 months of median follow-up, severe early–late toxicity (G3) was reported in terms of fibrosis and breast retraction, both with an incidence of 3.24%, mostly in the 3DCRT group. Oncological outcomes at a median follow-up of 2.4 years reported 141/154 (91.5%) patients alive and free from any event and 6 (3.9%) isolated locoregional recurrences. At 3 years, disease-free survival and overall survival were 94.8% and 98%, respectively.
Conclusions
Weekly ultra-hypo fractionated partial breast RT seems feasible and effective. Toxicity was mild, local control was acceptable, and overall survival was 98% at 3 years. Rates of severe toxicity were reduced with the IMRT technique.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract